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rates increasing only slightly over the same 30-beat period. These 
diabetics had other evidence of vagal damage, with abnormal 
responses to the Valsalva manoeuvre and reduced R-R interval 
variation. The results of the drug studies on the three controls 
confirm that the reflex is mediated through the vagus.
In  1895 H i 1 Is suggested that changes in posture m ight provide 
a “ most delicate test of the condition of the vasomotor mech­
anism ,” yet surprisingly little attention has been paid to the 
normal heart-rate response to standing. It is well recognised 
that there is a transient fall in blood pressure on standing, with 
stimulation of the carotid baroreceptors and consequent reflex 
tachycardia and peripheral vasoconstriction.1 A lthough it has 
long been known that in normal people the heart rate increases 
on stand ing/ the immediate heart-rate response has only 
recently been briefly d ocum en ted .S o  far as we are aware, the 
characteristic pattern that we describe has not previously been 
analysed in detail.
A lthough our results were first obtained from an accurate 
R-R interval analysis by computer, this study shows that heart- 
rate changes may also be detected with routine electrocardio­
graphy. As loss of a normal response is due to vagal damage, this 
provides the basis for a simple test of autonomic function that 
has considerable advantages over those now in use. Measurement 
of the 30:15 ratio gives a simple numerical value that reflects the 
presence or absence of the relative bradycardia. W hen the ratio 
is 1 0 0  or less vagal damage is probably present, although a value 
of less than 1-00 does not necessarily indicate more severe 
damage, as it will occur when there is a slight increase in 
heart rate over the 30-beat period. In  the most severe cases, in
which there is no change in heart rate on standing, the value will 
be exactly 1 *00.
This test is simple to use and requires only a standard 
electrocardiograph and the ability of the patient to stand up. It  is 
not effort-dependent and, so far as we know, cannot readily be 
“ cheated.” It correlates well with other recognised tests of 
cardiovascular reflex function in diabetes, is objective, requires 
no special patient co-operation, and is readily applicable as an 
outpatient procedure.
We thank Dr W G Macfie for allowing us to study subjects from a 
primary prevention trial of ischaemic heart disease, and Dr P J 
Watkins for his initial suggestion that we should look at this reflex 
response.
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SHORT REPORTS
Functions of phagocytic cells in chronic mucocutaneous candidiasis
Chronic mucocutaneous candidiasis (CMC) is a group of uncommon 
immunodeficiency disorders characterised by chronic infection of the 
skin, nails, and mucosal surfaces caused by Candida albicans. There 
are few reports about the functions of phagocytic cells in C M C .1-3 
This led us to investigate phagocytosis and intracellular killing of 
Candida by granulocytes and monocytes in CM C with a recently- 
developed technique.
Patients, methods, and results
Leucocyte functions were tested in five patients (two men (cases 2 and 5) 
and three women (1, 3, and 4)) with CM C. In four of these patients the 
Candida infection was limited to the skin, nails, and mucous membranes; 
the fifth patient (case 1) also suffered from recurrent bacterial infections 
(affecting the respiratory tract) and had the most severe candidiasis. Case 4 
also suffered from hypoadrenalism and hypoparathyroidism.
The method for measuring phagocytosis and intracellular killing by 
C albicans has been reported.1 To prevent a decrease in the number of the 
yeast cells caused by clumping of the yeast during the test period C albicans 
was precultured for at least five days at 30 C. Phagocytosis was assessed from 
the decrease in the number of extracellular Candida determined in a haema- 
cytometer. The rate of intracellular killing was determined microbiologically 
from the decrease in the number of viable Candida after lysis of the phago­
cytic cells.
In all patients phagocytosis of C albicans by granulocytes was normal in 
the presence of both normal serum and the patient’s serum. Phagocytosis 
by monocytes of cases 1, 2, 4, and 5 was in a normal range (93-8-98-9'’;,), 
whereas the monocytes of case 3 showed slightly diminished phagocytosis 
(90 0'\,). The intracellular killing by granulocytes in the presence of normal 
serum or patient’s serum was normal in all patients.
In the presence of normal serum the intracellular killing by monocytes 
was normal in two patients (cases 1 and 2), whereas two patients (4 and 5) 
showed hyperactive killing (>70'.'„ at 60 minutes) (see figure). Case 3 showed 
a slightly diminished killing. When patient’s monocytes were used together 
with patient’s serum, however, both cases 1 and 2 showed diminished intra­
cellular killing and the results for cases 3, 4, and 5 were not altered (see
i/)c:
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figure). When normal monocytes were used together with patient’s serum, 
serum of case 2 showed increased intracellular killing, whereas with the 
serum of case 1 the intracellular killing was still diminished (see figure).
C om m en t
Concerning the functions of phagocytic cells in CM C Valdimarsson 
et alx reported normal intracellular killing by granulocytes in five 
patients, using the dye exclusion method/’ This method has the dis­
advantage of subjective microscopical judgment of C and id a  cells being 
stained. Phagocytosis and intracellular killing of bacteria by leucocytes 
was normal in a child with recurrent pyogenic infections, CM C, and 
defective neutrophil chemotaxis.2
We found that phagocytosis and intracellular killing by granulo­
cytes were normal in all patients, and that phagocytosis by monocytes
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was slightly diminished in one (case 3). Intracellular killing by mono­
cytes showed a heterogeneous picture: either the monocytes were 
hyperactive or defective in this respect. The hyperactive killing might 
be explained as a compensatory mechanism in chronic Candida infec­
tion. The slightly decreased killing by monocytes in case 3 was prob­
ably also due to diminished phagocytosis as our killing assay measures 
the overall result of phagocytosis and intracellular killing.
In cases 1 and 2 the killing defect was remarkable because this 
defect is serum-dependent. The conclusion that only the disturbance 
of intracellular killing is serum-dependent is justified, because the 
phagocytosis assay showed no difference between normal and patient’s 
serum. The question of whether the serum of these two patients con­
tains an inhibitor or lacks a stimulant is under investigation. In two 
patients with CM C an inhibitor of intracellular killing of Candida by 
granulocytes has been reported.3
We thank Dr C. M  R Weemaes (Nijmegen), Dr G Hendrickx and Dr D B 
de Geer (Utrecht), and Dr R Schuurman (Rotterdam) for referring their 
patients. This study was supported by the J A Cohen Institute of Radio­
pathology and Radiation Protection.
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Prophylaxis with deglycyrrhizinised 
liquorice in patients with healed 
gastric ulcer
Recurrence of gastric ulceration after medical treatment is common, 
with recorded rates of 40 “o1 and 60 % 2 in the first two years. The use 
of ulcer-healing drugs to prevent relapse has received relatively little 
attention, though carbenoxolone has been used, but with little 
success/1 Aji acceptable prophylactic drug would be of considerable 
value in the management of gastric ulceration, and we undertook 
a trial of deglycyrrhizinised liquorice (DGL) to assess its merit in 
this respect.
Patients, methods, and results
Forty-one patients (23 men, 18 women) with benign chronic gastric 
ulceration, in whom complete ulcer healing had been shown both radio- 
logically and endoscopically within the previous four weeks, were selected 
for this study. All were aged under 75, and women of child-bearing age were 
excluded.
The trial was a double-blind controlled study, in which participants 
received five capsules a day, each containing either 450 mg of D G L  (Ulccdal) 
or an identical placebo. A normal diet was allowed and alcohol and tobacco 
were permitted in moderation. Antacids were taken as required. We reviewed 
the patients monthly for recurrence of symptoms, and a full haematological 
and biochemical profile was taken at each visit. Gastroscopy and barium-meal 
examinations were performed at six-monthly intervals, or earlier if dyspeptic 
symptoms arose in the meantime. Patients were followed up for at least 
two years or until the ulcer recurred.
On completion of the study eight patients had withdrawn, leaving 33 
patients for analysis, of whom 22 had received placebo and 11 D G L . The 
composition of these groups and the ulcer recurrence rate on D G L  and 
placebo is shown in the table. Eighteen patients developed a further gastric 
ulcer: five were receiving D G L  and 13 placebo. This represents a relapse 
rate during follow-up of 45 % for D G L  and 59 % for placebo. This difference
Comparative clinical data (ranges given in parentheses) and ulcer recurrence 
rate in 33 patients with a healed chronic gastric ulcer treated prophylactically 
with either deglycyrrhizinised liquorice (DGL) or placebo
D G L Placebo
No of patients 11 22
Mean age (years) 61 (44-74) 54 (39-74)
Sex: Male 6 12
temale • • • • • • • • •• •• 5 10
Mean duration of symptoms (years) 7 (1-15) 5 (1-20)
Mean duration of treatment (months) 16 (4-29) 12 (5-24)
Recurrent ulcer 5 13
°i, Recurrence . . 45* 59*
^Difference not significant.
is not significant. Seventy-eight per cent of the total recurrences occurred 
within the first 10 months of prophylaxis.
Reasons for withdrawal from the trial were defection from follow-up 
(five patients) and intercurrent illness (three patients). No clinical, bio­
chemical, or haematological abnormality was detected during treatment and 
no evidence of long-term toxicity was found.
C om m en t
A compound capable of preventing the recurrence of gastric 
ulceration would have considerable medical, social, and economic 
importance. Because the mechanism of gastric ulcer recurrence is 
unknown the choice of a suitable test compound cannot be entirely 
rational. We chose D G L  because of its reputed effectiveness in 
healing peptic ulceration1 (although this has been disputed5) and 
its lack of side effects. It has not previously been used prophylactically 
in man, but has been shown to protect against gastric ulceration in 
pylorus-ligated rats. D G L  in the dosage used in our study is not an 
effective prophylactic of chronic gastric ulceration, though the 
recurrence rate was lower in the treated patients than in the placebo 
group. Nevertheless, the patients’ acceptance of treatment combined 
with regular endoscopy and barium-meal studies was extremely 
good, which suggests that prolonged treatment and follow-up could 
be acceptable to informed patients.
Without precise information on the aetiology of gastric ulceration, 
the choice of further agents as potential prophylactics must be partly 
intuitive. Indeed, we cannot be certain that ulcer-healing agents will 
have any pharmacological activity as prophylactics. Nevertheless, we 
believe that the search for an effective prophylactic should continue, 
and suggest that the ideal characteristics of such a drug should be 
infrequent dosage, low cost, lack of side effects, and absence of long­
term ill effects, tolerance, or teratogenicity.
We thank Mrs E M  McCrcery and Miss T M  Hughes for typing the 
manuscript and Boehringer Ingleheim Ltd for supplying active drug and 
placebo.
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